Receptors, Tumor Necrosis Factor
"Receptors, Tumor Necrosis Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.
| Descriptor ID |
D018124
|
| MeSH Number(s) |
D12.776.543.750.705.852.760
|
| Concept/Terms |
Receptors, Tumor Necrosis Factor- Receptors, Tumor Necrosis Factor
- Receptors, Cachectin
- Tumor Necrosis Factor Receptors
- TNF Receptor
- Receptor, TNF
- TNF Receptors
- Tumor Necrosis Factor Receptor
- Cachectin Receptors
- Receptors, TNF
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Tumor Necrosis Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Tumor Necrosis Factor".
- Receptors, Tumor Necrosis Factor
- B-Cell Activation Factor Receptor
- B-Cell Maturation Antigen
- CD40 Antigens
- Etanercept
- fas Receptor
- Glucocorticoid-Induced TNFR-Related Protein
- Ki-1 Antigen
- Lymphotoxin beta Receptor
- Receptor Activator of Nuclear Factor-kappa B
- Receptors, Ectodysplasin
- Receptors, OX40
- Receptors, TNF-Related Apoptosis-Inducing Ligand
- Receptors, Tumor Necrosis Factor, Member 14
- Receptors, Tumor Necrosis Factor, Member 25
- Receptors, Tumor Necrosis Factor, Type I
- Receptors, Tumor Necrosis Factor, Type II
- Transmembrane Activator and CAML Interactor Protein
- Tumor Necrosis Factor Decoy Receptors
- Tumor Necrosis Factor Receptor Superfamily, Member 7
- Tumor Necrosis Factor Receptor Superfamily, Member 9
- TWEAK Receptor
This graph shows the total number of publications written about "Receptors, Tumor Necrosis Factor" by people in this website by year, and whether "Receptors, Tumor Necrosis Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 2 | 3 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2013 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Tumor Necrosis Factor" by people in Profiles.
-
Comparison of Aptamer-Based and Antibody-Based Assays for Protein Quantification in Chronic Kidney Disease. Clin J Am Soc Nephrol. 2022 03; 17(3):350-360.
-
Enhancement of Ovarian Tumor Detection by DR6-Targeted Ultrasound Imaging Agents in Laying Hen Model of Spontaneous Ovarian Cancer. Int J Gynecol Cancer. 2016 10; 26(8):1375-85.
-
Association of Immunosuppression with DR6 Expression during the Development and Progression of Spontaneous Ovarian Cancer in Laying Hen Model. J Immunol Res. 2016; 2016:6729379.
-
Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology. 2013 Oct; 58(4):1461-73.
-
Tuberculosis infections and tumor necrosis factor alpha antagonists. Am J Ther. 2013 Jan; 20(1):73-8.
-
Virus expanded regulatory T cells control disease severity in the Theiler's virus mouse model of MS. J Autoimmun. 2011 Mar; 36(2):142-54.
-
Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010 Jun 15; 201(12):1796-805.
-
Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. J Rheumatol. 2009 May; 36(5):914-7.
-
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer. 2008 Jul; 61(1):82-90.
-
Etanercept therapy in patients with a positive tuberculin skin test. Clin Exp Rheumatol. 2007 Sep-Oct; 25(5):743-5.